Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Anaxagoras who wrote (899)	11/25/1997 2:10:00 PM
From: Tunica Albuginea	Respond to of 7041

Anaxagoras, Re the half life of phentol. + 19 min. This is the company's PR again. Studies released to the investment wires. So far everything that they've released has been labeled as shoddy work. The point is that they haven't proven anuthing so far. -it is all blue smoke and mirrors. -There is nothing written up in a peer reviewes medical jour such as - the New England Journ of Medicine -the Archives of Iner Med -Medicine - The Jour of Med -The JAMA -the Jour of Endocrinol & Metabolism -Endocrinology etc, etc etc. -There is nothing published in one of the " thowaway Journals we receive( they often have very prliminary studies..] -There is NOTHING presented at any of the annual meetings ,in Urology, Medicine, Endocrinology,. There is a single or so article published by the guy who sold Phentol to Zona ( I forget his name) which is unsupported bu all the previous and current literat and who made out like a bandit at Zona's expense. I am sorry if I don't get teary eyed with Zona. You've got to do beter than this. TA